Policy & Regulation
7 March 2025 - Danish pharmaceutical company ALK-Abelló A/S (ALK) (CPH:ALK-B) said on Friday that it has received approval from Health Canada for its ACARIZAX tablet to treat children aged five...
7 March 2025 - Kancera AB (Nasdaq First North Premier Growth Market:KAN), a developer of anti-inflammatory drugs in the field of cardiovascular diseases, said on Friday that it has signed a letter of ...
7 March 2025 - US-based drug discovery and development company Bantam Pharmaceutical announced on Thursday that it is proceeding with a Phase 1 clinical trial evaluating BTM-3566 in relapsed/refractor...
7 March 2025 - Biotechnology company Integral Molecular, which focuses on membrane proteins and antibodies, announced on Thursday that the first patient has been dosed with its out-licensed anti-Claud...
7 March 2025 - Clinical-stage biotech company ImmunoGenesis announced on Thursday that the first patient has been dosed in its Phase 1/2 clinical trial of its hypoxia reversal agent IMGS-101 (evofosfa...
6 March 2025 - Clinical-stage pharmaceutical company Plus Therapeutics Inc (Nasdaq:PSTV) announced on Thursday that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) ...